Scandinavian Journal of Rheumatology最新文献_第9页

Total iron binding capacity: an independent predictor of prognosis for pulmonary arterial hypertension in systemic lupus erythematosus. 总铁结合能力：系统性红斑狼疮肺动脉高压预后的独立预测因素。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-08-22 DOI: 10.1080/03009742.2023.2240586

J Xiong, Y Peng, J Li, S Cai, R Wu

{"title":"Total iron binding capacity: an independent predictor of prognosis for pulmonary arterial hypertension in systemic lupus erythematosus.","authors":"J Xiong, Y Peng, J Li, S Cai, R Wu","doi":"10.1080/03009742.2023.2240586","DOIUrl":"10.1080/03009742.2023.2240586","url":null,"abstract":"Objective: To investigate the role of parameters of iron metabolism in systemic lupus erythematosus (SLE) patients with pulmonary arterial hypertension (PAH).Method: This was a prospective observational study recruiting patients diagnosed with systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH). Patients with other factors that might lead to PAH were excluded from the study. All patients were assessed for PAH every 1-3 months and were followed up for 6 months. The primary outcome was considered improved if the grade of risk stratification declined at the endpoint; otherwise, it was considered unimproved.Results: In total, 29 patients with SLE-PAH were included in this study. The mean of serum ferritin was higher than normal, and total iron binding capacity (TIBC) decreased in 48% of patients. Correlation analyses showed that serum iron (SI) was negatively correlated with World Health Organization functional class (WHO-FC) (r = -0.409, p = 0.028), and positively correlated with Six-Minute Walk Test distance (6MWD) (r = 0.427, p = 0.021) and tricuspid annular plane systolic excursion (TAPSE) (r = 0.388, p = 0.037). Primary outcomes improved in 12 patients at the endpoint, and univariate logistic regression analyses indicated that TIBC was associated with improved primary outcomes in patients with SLE-PAH (odds ratio 12.00, 95% confidence interval 1.90-75.72).Conclusion: SI was negatively correlated with WHO-FC, and positively correlated with 6MWD and TAPSE. Furthermore, TIBC was associated with improved outcomes of patients with SLE-PAH, which could be an independent predictor of prognosis. Further research is needed to verify the findings.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"44-48"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impaired development of B cells with PRF1 variants in an adult. 具有PRF1变体的B细胞在成人中发育受损。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-12-28 DOI: 10.1080/03009742.2023.2256090

T Tsubata, N Umezawa, T Yasumi, H Kanegane, S Yasuda

引用次数: 0

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-06-20 DOI: 10.1080/03009742.2023.2216046

Z R Stisen, S M Nielsen, S B Ditlev, M Skougaard, A Egeberg, M Mogensen, T S Jørgensen, L Dreyer, R Christensen, L E Kristensen

{"title":"Treatment-related changes in serum neutrophil gelatinase-associated lipocalin (NGAL) in psoriatic arthritis: results from the PIPA cohort study.","authors":"Z R Stisen, S M Nielsen, S B Ditlev, M Skougaard, A Egeberg, M Mogensen, T S Jørgensen, L Dreyer, R Christensen, L E Kristensen","doi":"10.1080/03009742.2023.2216046","DOIUrl":"10.1080/03009742.2023.2216046","url":null,"abstract":"Objectives: Obesity and psoriatic arthritis (PsA) have a complicated relationship. While weight alone does not cause PsA, it is suspected to cause worse symptoms. Neutrophil gelatinase-associated lipocalin (NGAL) is secreted through various cell types. Our objective was to assess the changes and trajectories in serum NGAL and clinical outcomes in patients with PsA during 12 months of anti-inflammatory treatment.Method: This exploratory prospective cohort study enrolled PsA patients initiating conventional synthetic or biological disease-modifying anti-rheumatic drugs (csDMARDs/bDMARDs). Clinical, biomarker, and patient-reported outcome measures were retrieved at baseline, and 4 and 12 months. Control groups at baseline were psoriasis (PsO) patients and apparently healthy controls. The serum NGAL concentration was quantified by a high-performance singleplex immunoassay.Results: In total, 117 PsA patients started a csDMARD or bDMARD, and were compared indirectly at baseline with a cross-sectional sample of 20 PsO patients and 20 healthy controls. The trajectory in NGAL related to anti-inflammatory treatment for all included PsA patients showed an overall change of -11% from baseline to 12 months. Trajectories in NGAL for patients with PsA, divided into treatment groups, showed no clear trend in clinically significant decrease or increase following anti-inflammatory treatment. NGAL concentrations in the PsA group at baseline corresponded to the levels in the control groups. No correlation was found between changes in NGAL and changes in PsA outcomes.Conclusion: Based on these results, serum NGAL does not add any value as a biomarker in patients with peripheral PsA, either for disease activity or for monitoring.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"21-28"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9723019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy outcome in patients with a medical history of immunoglobulin A vasculitis: a case-control study. 有免疫球蛋白 A 血管炎病史患者的妊娠结局：一项病例对照研究。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-07-13 DOI: 10.1080/03009742.2023.2226518

M-C Besse, F Perrotin, A Aouba, S Gallou, A Karras, E Pillebout, G Urbanski, J-S Allain, C Merlot, S Humbert, Y Ramdani, N Ferreira-Maldent, F Maillot, A Audemard-Verger

{"title":"Pregnancy outcome in patients with a medical history of immunoglobulin A vasculitis: a case-control study.","authors":"M-C Besse, F Perrotin, A Aouba, S Gallou, A Karras, E Pillebout, G Urbanski, J-S Allain, C Merlot, S Humbert, Y Ramdani, N Ferreira-Maldent, F Maillot, A Audemard-Verger","doi":"10.1080/03009742.2023.2226518","DOIUrl":"10.1080/03009742.2023.2226518","url":null,"abstract":"Objective: Data on obstetric outcomes in patients with a history of immunoglobulin A vasculitis (IgA-V) are lacking. The aim of this study was to assess maternal, neonatal, and vasculitis outcomes during pregnancy.Method: We conducted a French retrospective case-control study. Pregnancies of patients with a history of IgA-V (cases) were retrospectively studied and compared to pregnancies in women who developed IgA-V after their pregnancies and to pregnancies in healthy women (controls).Results: Twenty-six pregnancies in patients with a history of IgA-V were included and compared to 15 pregnancies in women who later developed IgA-V and 52 pregnancies in healthy women. Both gestational hypertension and pre-eclampsia were more frequent in the case group than in the other groups (23% vs 0% vs 0%, p < 0.01; 12% vs 7% vs 0%, p = 0.04). Hypertensive disorder of pregnancy occurred more frequently in patients with pre-existing kidney disease (78% vs 12%, p < 0.01). Caesarean section was more often performed in the case group than in the other groups (27% vs 0% vs 10%, p = 0.04). No foetal loss or maternal deaths occurred. There were no differences in delivery term or birth weight. No vasculitis flares were observed during pregnancy.Conclusion: Women with a history of IgA-V appear to be at higher risk for gestational hypertension and pre-eclampsia, especially in cases with renal involvement; however, both mother and newborn outcomes appear to be favourable.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"36-43"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies. 贝利木单抗治疗伴有抗磷脂抗体的系统性红斑狼疮患者的难治性免疫性血小板减少症。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-08-31 DOI: 10.1080/03009742.2023.2247881

J Dong, L Zhao, L Pan, H Wang, L Wang

{"title":"Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies.","authors":"J Dong, L Zhao, L Pan, H Wang, L Wang","doi":"10.1080/03009742.2023.2247881","DOIUrl":"10.1080/03009742.2023.2247881","url":null,"abstract":"Objective: To observe the effect of belimumab treatment in refractory anti-phospholipid antibody-associated immune thrombocytopenia with systemic lupus erythematosus (SLE).Method: Four SLE patients with refractory anti-phospholipid antibody-associated immune thrombocytopenia were included in this one-arm observational study. Inclusion criteria were a diagnosis of SLE according to 1997 American College of Rheumatology criteria, severe immune thrombocytopenia (platelets <30 × 109/L), no bleeding symptoms, lack of satisfactory response to traditional treatment, and high-titre anti-phospholipid antibodies. All patients received belimumab (Benlysta®) for 6 months.Results: The mean platelet count was 21.8 × 109 cells/L, ranging between 16 and 29 × 109/L at baseline, 123.3 × 109/L at 1 month, and 172.5 × 109/L at the end of 6 months after belimumab treatment. No bleeding complications occurred during the entire follow-up period.Conclusion: In this study, belimumab reduced the anti-phospholipid antibodies while increasing the platelet count in SLE patients with anti-phospholipid antibody-associated immune thrombocytopenia.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"59-62"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10495172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Call for Papers: Special Issue on Interstitial Lung Disease in the Setting of Rheumatic Disorders. 征稿启事：风湿性疾病引起的间质性肺病特刊。

IF 2.1 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-12-28 DOI: 10.1080/03009742.2024.2297595

引用次数: 0

Thiemann's disease: a very rare bone disorder. 蒂曼氏病:一种非常罕见的骨骼疾病。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-12-28 DOI: 10.1080/03009742.2023.2274657

D Bulut Gökten, R Mercan

引用次数: 0

'Pencil-in-cup' deformity may not be specific for psoriatic arthritis. “杯状铅笔”畸形可能不是银屑病关节炎的特异性。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-12-28 DOI: 10.1080/03009742.2023.2266908

T Prasad, C-Cs Liu, C Siva

引用次数: 0

Systemic sclerosis: changes in the incidence rates in the Finnish population during the years 1999-2018. 系统性硬化症：1999-2018年间芬兰人口发病率的变化。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-07-13 DOI: 10.1080/03009742.2023.2217620

S Kortelainen, M Käyrä, S Hurme, J Paltta, L Pirilä, J Huhtakangas

{"title":"Systemic sclerosis: changes in the incidence rates in the Finnish population during the years 1999-2018.","authors":"S Kortelainen, M Käyrä, S Hurme, J Paltta, L Pirilä, J Huhtakangas","doi":"10.1080/03009742.2023.2217620","DOIUrl":"10.1080/03009742.2023.2217620","url":null,"abstract":"Objective: The aim of our study was to examine changes in the incidence of systemic sclerosis (SSc) in Finland using two different classification criteria.Method: Medical records of patients who had been registered with ICD-10 code M34 from 1999 to 2018 in two university hospitals were reviewed retrospectively. This period was divided into 5 year periods: 1999-2003, 2004-2008, 2009-2013, and 2014-2018. Using American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2013 criteria and clinical findings, we reclassified patients into four groups: diffuse SSc, limited SSc, sine SSc, or early SSc. In the same population, we also investigated whether the ACR 1980 criteria were fulfilled.Results: In 1999-2018, 246 new patients with SSc and 45 patients with early SSc were identified using ACR/EULAR 2013 criteria. Of these patients, 70 fulfilled the ACR 1980 criteria. Using ACR/EULAR 2013 criteria, the increase in new diagnoses was statistically significant when comparing the fourth period with the first period (p = 0.0012). The increase was due to a rise in limited SSc. Mean annual incidence rates in these groups were 0.9, 1.2, 1.9, and 2.8 per 100 000 inhabitants ≥ 16 years old. An increasing trend was also seen when using ACR 1980 criteria, but this was not statistically significant.Conclusion: The incidence of SSc increased during the period between 1999-2003 and 2014-2018 using ACR/EULAR 2013, but not using ACR 1980 criteria. The increase was detected within a limited SSc subclass, owing to more sensitive classification criteria.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"29-35"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9776730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population. 银屑病关节炎：疗效有所改善，但性别差异依然存在--对挪威门诊患者进行的为期 5 年的随访研究。

IF 2.2 4区医学

Scandinavian Journal of Rheumatology Pub Date : 2024-01-01 Epub Date: 2023-09-01 DOI: 10.1080/03009742.2023.2247703

K Łosińska, B Michelsen, A Kavanaugh, M Korkosz, G Haugeberg

{"title":"Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population.","authors":"K Łosińska, B Michelsen, A Kavanaugh, M Korkosz, G Haugeberg","doi":"10.1080/03009742.2023.2247703","DOIUrl":"10.1080/03009742.2023.2247703","url":null,"abstract":"Objective: This study aimed to explore long-term changes in disease activity and remission rates, and potential sex-related differences in these outcomes, in psoriatic arthritis (PsA) patients treated in an outpatient clinic.Method: This prospective longitudinal cohort study included 114 patients. The Disease Activity Index for Psoriatic Arthritis (DAPSA), clinical DAPSA (cDAPSA), 28-joint Disease Activity Score (DAS28), Simplified and Clinical Disease Activity Indices (SDAI, CDAI), Boolean remission for PsA, and minimal and very low disease activities (MDA, VLDA) were assessed. For group characteristics, parametric statistics and linear regression were used.Results: At 5 year follow-up, improvement was noted for multiple measures reflecting disease activity and patient-reported outcomes. Statistically significant increases in remission rates were observed using DAS28 (+21.2%), CDAI (+9.7%), and cDAPSA (+7.6%), but not SDAI, DAPSA, Boolean remission, MDA, or VLDA. During the study period, the proportion of patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs) increased from 37.7% to 48.3% (p = 0.007). At baseline, women reported higher pain and fatigue, and had higher tender joint counts, DAPSA, cDAPSA, SDAI, CDAI, and DAS28 than men. Despite higher mean baseline C-reactive protein, men more often achieved remission, regardless of the definition applied. A higher proportion of men than women was treated with bDMARDs (baseline: 46.6% vs 28.6%; follow-up: 58.6% vs 33.9%).Conclusion: This study adds evidence supporting recent improvements in PsA outcomes. Women had higher disease activity and were less likely to achieve remission than men. Despite progress in achieving remission goals, there is still room for improvement in therapeutic approaches for PsA patients.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"10-20"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10120362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0